Grifols confirmed on Monday, before the market opened, that the Catalan company’s family shareholders have reached an agreement with the Brookfield fund to evaluate a possible joint takeover bid (OPA) for the entire share capital of the blood derivatives company.
In a communication sent to the National Securities Market Commission (CNMV), Grifols explains that its board of directors, meeting in an extraordinary session, received a request this Sunday through the family shareholders of Grifols and Brookfield Capital Partners “to allow access to certain information” of the company in order to carry out a ‘due diligence’ process in relation to a possible acquisition of Grifols shares.
At the meeting, it was reported that the purpose of the transaction would be to delist Grifols if the operation is finally carried out.
“The company is currently unaware of whether or not this transaction will be carried out and is completely unaware of the terms under which it might be carried out,” Grifols told the CNMV.
With this announcement, the Catalan company confirms the information published this Monday by the newspaper ‘Cinco Días’, which values 100% of Grifols at 5.5 billion euros.
As soon as this possible takeover bid was confirmed, the CNMV proceeded to suspend Grifols’ trading on the Stock Exchange with immediate effect and as a precautionary measure. Grifols’ shares closed last Friday at a price of 8.99 euros per share following gaining more than 4% in the session.
